注射用丹参多酚酸对内囊预警综合征脑梗死患者的疗效及血清S-100β蛋白的影响

Effect of Salvianolic Acids for Injection on S-100β protein and its curative effect in patients with cerebral infarction coming from capsular warning syndrome

目的探讨注射用丹参多酚酸对内囊预警综合征进展为脑梗死的疗效及患者血清S-100β蛋白的影响。方法2015年1月—2018年12月安阳市第六人民医院诊治的内囊预警综合征进展为脑梗死患者40例,随机分为对照组和治疗组。对照组每日静脉滴注0.9%生理盐水250 mL;治疗组每日静脉滴注注射用丹参多酚酸0.13 g加入0.9%生理盐水250 mL。治疗前后检测血清S-100β蛋白水平和应用美国国立卫生研究院卒中量表(NIHSS)进行神经功能缺损程度评定。结果治疗组和对照组在入院第1天(治疗前)血清S-100β水平和神经功能缺损程度评分无显著差异;第14天治疗组血清S-100β水平和神经功能缺损程度评分低于对照组(P<0.05),同时低于同组治疗前的相应水平(P<0.05);第30天NIHSS评分治疗组低于对照组(P<0.05),且显著低于同组治疗前的(P<0.01)。结论注射用丹参多酚酸对内囊预警综合征进展为脑梗死的患者具有减轻神经胶质细胞损伤,减缓脑梗死进展,促进神经功能修复的作用。

Objective To investigate the therapeutic effect of Salvianolic Acids for Injection on the progression of internal capsule warning syndrome to cerebral infarction and the effect on S-100βprotein levels in serum.Methods 40 patients with cerebral infarction coming from capsular warning syndrome were randomly divided into two groups.Based on conventional therapy,the control group was treated with 0.9%normal saline 250 mL every day;while in the treatment group,0.13 g of Salvianolic Acids for Injection and 250 mL of 0.9%normal saline were given intravenously every day.The changes of S-100βprotein levels and NIHSS score were compared in the two groups before and after the treatment.Results There was no significant difference in NIHSS score and the level of S-100βprotein between the treatment group and the control group on the first day before treatment.After 14 days treatment,the level of S-100βprotein and NIHSS score in treatment group were lower than those in control group,also lower than those in the treatment group before treatment(P<0.05);The NIHSS score of treatment group was lower than control group after thirty days(P<0.05),and was significantly lower than scores of treatment group before treatment(P<0.01).Conclusion The Salvianolic Acids for Injection can relieve the damage of neuroglia cells,slow down the progress of cerebral infarction and promote the repair of nerve function in patients with cerebral infarction coming from capsular warning syndrome.